TAR 0520
Alternative Names: TAR-0520Latest Information Update: 23 Apr 2024
At a glance
- Originator Tarian Pharma
- Class Antiglaucomas; Antihypertensives; Bromobenzenes; Diamines; Eye disorder therapies; Imidazoles; Quinoxalines; Skin disorder therapies; Small molecules; Vasoconstrictors
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Skin disorders
Most Recent Events
- 12 Apr 2024 Tarian Pharma plans a phase I trial for Skin disorders in the US (http://www.isrctn.com/ISRCTN12940582)
- 02 Apr 2024 Preclinical trials in Skin disorders in USA (Topical) (http://www.isrctn.com/ISRCTN12940582)